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Objectives:Modern management of myeloma has significantly improved survival, with increasing numbers of
patients living beyond a decade. However, little is known about the long-term cardiovascular and respiratory
status of intensively treated and multiply relapsed survivors.
Methods: We performed detailed cardiovascular and respiratory evaluations in patients with intensively
treated, advanced but stable myeloma. All patients had received at least two lines of treatment, including
at least one haematopoietic stem cell transplantation procedure, but had stable, controlled disease and
were off active treatment at the time of evaluation.
Results: Thirty-two patients with a median duration of 6 years (range 2–12) from original diagnosis of myeloma
and three lines (range 2–6) of treatment were evaluated. Despite normal physical examination in the majority,
there was a high prevalence of sub-clinical cardiac and respiratory dysfunction, reflected by abnormalities of
electrocardiography (45%), echocardiography (50%), serum N-terminal pro-B-type natriuretic peptide level
(NT-pro-BNP, 50%), and pulmonary function testing (45%). NT-pro-BNP level correlated negatively with
quality of life (P= 0.012) and positively with serum ferritin (P= 0.027). Dyspnoea score correlated with
BMI (P= 0.001). Risk factors for cardiovascular disease (obesity, hypertension, hyperlipidaemia, and
hyperinsulinaemia) were common.
Discussion: Even in the absence of overt clinical features, the majority of intensively treated long-term
survivors of myeloma have established cardiovascular and/or respiratory dysfunction, above levels
expected in the general population of a similar age.
Conclusion: This study supports routine screening and lifestyle modification combined with primary and
secondary preventive strategies to reduce cardiovascular and respiratory disease and to preserve quality
of life in transplanted myeloma patients.
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Introduction
The life expectancy of patients with myeloma has
increased significantly over the last decade. Although
the vast majority of patients remain incurable,
disease control is possible with an increasing array of
novel agents along with improved supportive care
measures, and many patients now live beyond a
decade with their disease.1,2 In addition to the direct
effects of the disease, exposure to multiple anti-
myeloma agents is associated with an accumulation
of side effects affecting many organ systems. Whilst
some may be reversible and short lived, others are insi-
dious in onset, and result in permanent damage or ‘late
effects’.
‘Late effects’ is perhaps best defined as per the NCI
definition as ‘A health problem that occurs months or
years after a disease is diagnosed or after treatment has
ended. Late effects may be caused by cancer or cancer
treatment. They may include physical, mental, and
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social problems and second cancers’. In myeloma,
such ‘late effects’ may be additive or synergistic with
other cytotoxic and supportive agents, and with
organ damage caused by myeloma or other processes
such as the degenerative conditions commonly experi-
enced by an ageing population.3,4 Patients with
myeloma are progressively compromised due to a
complex set of complications related to myeloma, its
treatment, and advancing age.5
Although ‘late effects’ screening practices have been
recommended following haematopoietic stem cell
transplantation (HSCT),6 and many patients with
myeloma have HSCT, the situation is arguably more
complex than for many other HSCT indications as
myeloma is a multisystem disease; transplant pro-
cedures are not usually curative (with relapse being
common after many allogeneic procedures) and
patients typically have several lines of anti-myeloma
treatment in a lifetime (including more than one trans-
plant procedure).
The previously limited prognosis of myeloma com-
bined with the long-term horizon of cardiovascular
risk factors have meant that screening, modification
and treatment were not a priority and perhaps difficult
to justify. The improving prognosis combined with
increasing recognition that intensive cytotoxic
therapy and HSCT are associated with ‘late’ cardio-
vascular and respiratory effects may mean more
active screening and treatment of cardiovascular risk
factors is warranted.4,7–9 However, data remain scarce.
The aim of this exploratory study was to character-
ize the cardiovascular and respiratory status of a
cohort of patients with intensively treated (i.e. trans-
planted), multiply relapsed but stable myeloma. Such
information would be useful in designing models for
comprehensive care in myeloma, aimed at maintaining
general health and quality of life in long-term
survivors.
Patients and methods
Design and eligibility – including consideration
of human rights
This cross-sectional observational study was con-
ducted in compliance with the EU GCP directive
and approved by Sheffield Teaching Hospitals NHS
Foundation Trust R&D Department following local
Research Ethics Committee review.10 Inclusion cri-
teria included diagnosis of ‘symptomatic myeloma’
by International Working Group criteria,1 a history
of initial treatment with induction therapy consoli-
dated by at least one HSCT procedure, followed by
at least one additional line of treatment for progressive
or relapsed disease. In order to eliminate the effects of
active myeloma and its treatment, only patients with
controlled disease, i.e. paraprotein plateau/non-pro-
gressive phase off active treatment or on maintenance
treatments for at least 3 months, were recruited.
Exclusion criteria included uncontrolled disease and
inability to give informed consent.
Assessments
Standardized data collection forms were used to
obtain information relating to previous management
of myeloma and all co-morbidities, based on medical
records and standardized patient history.
Standardized physical examinations of the cardiovas-
cular and respiratory systems were performed by
experienced (i.e. MRCP (UK) qualified) physicians.
Electrocardiography (ECG) was performed accord-
ing to standard protocols and electrocardiograms
were reviewed in a blinded fashion by a single
consultant cardiologist (EU specialist register).
Echocardiography was performed by sonographers
trained to UK national accreditation standards and
echocardiograms were reported by the reviewing echo-
sonographer according to British Society of
Echocardiography criteria.11 Serum N-terminal pro-
B-type natriuretic peptide (NT-pro-BNP) was
measured and values above 15 pmol/l (125 pg/ml)
were considered to be significantly raised in accord-
ance with published criteria for this age group.12
Spirometry was performed using a Viasys Microlab
spirometer, according to manufacturer’s instructions.
A restrictive picture was defined as FVC (forced
vital capacity) <80% of predicted with an FEV1
(forced expiratory volume in 1 second)/FVC ratio
>80%; an obstructive picture defined as FEV1/FVC
ratio <70% with FVC >80% predicted and mixed
picture defined as FVC <80% predicted and FEV1/
FVC <80%. Spirometry was considered normal if
not meeting any of above criteria.13 Maximal expira-
tory (MEP) and inspiratory (MIP) pressures were
measured, with lower limits of normal for individual
patients calculated using previously published
formulae.14
Body mass index (BMI) and nutritional status were
assessed using conventional clinical criteria.15 Serum
glucose, triglycerides, total cholesterol, insulin, and
ferritin were measured in the non-fasting state. Renal
function was assessed by calculation of creatinine
clearance (CrCl) using the Cockcroft–Gault formula,
and the appropriate stage of chronic kidney disease
(CKD) recorded.16
Assessment of symptoms and health-related
quality of life
Information regarding symptoms, functioning, and
quality of life was collected using EORTC QLQ-C30
questionnaires, which include dyspnoea scores.17
Statistical analysis
Descriptive statistics and non-parametric tests of sig-
nificance (Spearman’s rank correlation coefficient
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and Mann–Whitney ‘U’ test) were used. PASW
version 18 computer software was utilized for data
analysis. An r value of ≥0.4 was taken as a cut-off
for strength of correlation and P< 0.05 taken to
demonstrate significance.18
Results
Demographics and medical history
Thirty-two patients fulfilling the eligibility criteria
were recruited (17 males and 15 females) from a ter-
tiary referral centre. Ten further patients were
approached, but either declined to participate or
were deemed ineligible. For each variable recorded
data were available for at least 30 patients.
Median age at time of assessment was 60 years
(range 41–71) with median age at diagnosis 55 years
(range 36–69). Patients commenced treatment for
symptomatic myeloma in the years 1998–2008. The
median time from diagnosis was 6 years (range 2–12)
with median time of 5 years (range 1–11) since initial
HSCT. Patients had received a median of three
(range 2–6) lines of treatment. All patients had under-
gone at least one HSCT procedure: 29 (91%) at least
one autologous HSCT with high-dose melphalan con-
ditioning; 4 (13%) allogeneic HSCT; 10 (31%) two
HSCT procedures. Previous chemotherapy and radio-
therapy treatments are summarized below (Table 1),
and include the use of anthracycline chemotherapy
in 30 (94%) patients in the form of doxorubicin,
although with a relatively low cumulative dose
(<360 mg/m2). Two patients (6%) had received
donor lymphocyte infusions after allogeneic HSCT.
Thirteen patients (41%) were obese (BMI >30 kg/
m2); 7 (22%) were overweight (BMI 25–29.9 kg/m2);
11 (34%) had a normal BMI (18.5–24.9 kg/m2), and
1 patient (3%) was underweight (BMI <18.5 kg/m2).
CrCl was calculated for all patients. Of these, 13
(41%) patients had normal CrCl (≥90 ml/min, stage
1 CKD); 14 (44%) patients were in stage 2 CKD
(CrCl 60–89 ml/min); 3 (9%) patients in stage 3
CKD (CrCl 30–59 ml/min); and 2 (6%) had severe
or end-stage (stage 4–5) CKD (CrCl <30 ml/min).
Cardiovascular assessments
No patient had a history of cardiovascular adverse
events prior to diagnosis of myeloma; one patient suf-
fered from two episodes of polymorphic ventricular
tachycardia during and after active myeloma treat-
ment, both while being treated for intercurrent
sepsis. Heart sounds were normal on standardized
clinical examination in all 32 patients. Twenty-four
(75%) patients had no pitting oedema; seven (22%)
had below-knee oedema, and one (3%) had oedema
extending above the knee.
ECGs were analysed for 31 patients. Of these, 17
(55%) patients had ECGs within normal limits and
14 (45%) patients had at least one electrocardiographic
abnormality: three patients had limb lead criteria for
left ventricular hypertrophy (LVH) and five patients
had ECG repolarization abnormalities consistent
with LVH. Three patients had ECG evidence of left
atrial hypertrophy and three had a prolonged PR inter-
val whilst single patients had atrial fibrillation, isolated
left axis deviation, and complete right bundle branch
block.
Echocardiography assessments were available for 30
patients; 15 (50%) had normal echocardiograms and
for 15 (50%) abnormalities were found. Thirteen
patients had left atrial enlargement; six patients had
echocardiographic LVH; four had dilatation of the
proximal ascending aorta (including one patient with
an incidental congenital aortopathy with bicuspid
aortic valve); two patients had a dilated left ventricular
chamber in diastole; and one had pulmonary hyper-
tension. One patient had mild left ventricular systolic
Table 1 Demographics and treatment history of the cohort
(total 32 patients)
Patient demographics
Age at assessment Median 60 (range 41–71)
Age at diagnosis Median 55 (range 36–69)
Duration from diagnosis Median 6 years (range 2–12)
Sex 17 males, 15 females
Anti-myeloma treatment history
Lines of treatment received
(initial induction+HSCT*
counted as a single line)
Median 3 (range 2–6)
HSCT 29 (91%) at least one
autologous HSCT
4 (13%) allogeneic HSCT
10 (31%) two HSCT
procedures
2 (6%) donor lymphocyte
infusion following
allogeneic HSCT
Other anti-myeloma
chemotherapy
32 (100%)
cyclophosphamide
32 (100%) melphalan
32 (100%) high-dose
steroids
30 (94%) doxorubicin
27 (84%) vincristine
22 (69%) bortezomib
(intravenous)
19 (59%) thalidomide
4 (13%) lenalidomide
3 (9%) fludarabine
4 (13%) etoposide
2 (6%) cytarabine
2 (6%) cisplatin
4 (13%) interferon alpha
Radiation therapy 13 (41%) any radiotherapy
12 (38%) localized
radiotherapy only
1 (3%) total body irradiation
and localized radiotherapy
6 (19%) radiotherapy
involving thorax
Demographics and anti-myeloma treatment histories of all 32
patients included in the study. Previous anti-myeloma therapy
including haematopoietic stem cell transplant procedures,
chemotherapy, and radiation therapy is summarized.
*HSCT, haematopoietic stem cell transplantation.
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dysfunction but with a normal NT-pro-BNP level at
3 pmol/l (23 pg/ml). In total 19 (61%) of the 31
patients for whom ECG and/or echocardiography
were available had an abnormality of one or both.
Serum NT-pro-BNP level was available for all 32
patients and was raised above the threshold of
15 pmol/l (125 pg/ml) in 16 (50%) patients, with a
median level 16 pmol/l (133 pg/ml) (range
2–165 pmol/l (18–1400 pg/ml)). Serum ferritin levels
(median 517 pmol/l (230 μg/l), range 16–42
668 pmol/l (7–18 989 μg/l)) were raised above our
laboratory reference range (upper limit 337 pmol/l
(150 μg/l) for women <50 years; 899 pmol/l
(400 μg/l) for all other patients) in 10 (31%) patients,
over half of these markedly so (six >2000 pmol/l
(890 μg/l)) and serum NT-pro-BNP level correlated
significantly with serum ferritin (P= 0.027, r= 0.4).
Serum NT-pro-BNP results also correlated positively
with age (P= 0.001, r= 0.5), and negatively with
CrCl (P= 0.010, r=−0.5) as well as measures of
quality of life (see below). We did not observe a signifi-
cant correlation between abnormalities of echocardio-
graphy, ECG, or NT-pro-BNP level and cumulative
anthracycline dose, total number of lines of treatment,
or with various other potentially cardiotoxic agents,
such as cyclophosphamide and thoracic radiotherapy.
The relation between serum NT-pro-BNP and the
presence of ECG and echocardiographic abnormal-
ities was modest: five subjects had serum NT-pro-
BNP >15 pmol/l (125 pg/ml) but no abnormality in
ECG or echocardiography whilst 10 had an elevated
NT pro-BNP level and an abnormality in ECG or
echocardiography.
Respiratory assessments
By standardized clinical history, 3 of 32 patients had
previous respiratory diagnoses: emphysema (one
patient); bronchiectasis, asthma, and pulmonary
lobectomy (one patient); and pulmonary embolism
(one patient). Thirty patients (94%) had a normal
clinical respiratory examination; two patients had
abnormal examinations, one of whom had a prior
diagnosis of respiratory pathology.
Spirometry was undertaken in 31 patients, of whom
17 (55%) had normal spirometry results and 14 (45%)
had abnormal results. Of those patients with abnormal
results, five had a restrictive picture; two an obstruc-
tive picture; and seven a mixed picture.
The median value for percentage of predicted FEV1
attained was 79% (range 46–117%) and for FVC was
85% (range 43–116%). Median FEV1/FVC ratio
was 81 (range 43–100). Maximum respiratory press-
ures were recorded for 30 patients. MIP was below cal-
culated lower limit of normal in 10 (33%) (median
−54 cm H2O, range −12 to −102 cm H2O). For
MEP, eight (26%) were below calculated lower limit
of normal (median 96 cm H2O, range 12–138 cm
H2O).
Lifestyle and cardiovascular risk factors
Three patients (<10%) were current smokers, 12
smoked previously, and the remainder never smoked.
No patient reported exceeding the most conservative
interpretation of current UK National Health
Service recommendations of <21 units of alcohol per
week for men and <14 units for women.19
Eight (25%) patients gave a history of physician-
diagnosed hypertension; a further three (9%) patients
had either systolic blood pressure ≥140 mmHg and/
or diastolic blood pressure ≥90 mmHg on the lower
of two readings taken during structured clinical exam-
ination, sufficient to warrant follow-up by current cri-
teria.20 Of the patients previously diagnosed with
hypertension, five were already on anti-hypertensive
medication, two were not on any anti-hypertensives,
and medication history was unavailable for one.
Only one patient (already known to have type II dia-
betes mellitus) was already on lipid-lowering medi-
cation (simvastatin), but, in the non-fasting state, a
further 16 (50%) patients had total serum cholesterol
levels ≥5 mmol/l (median 5.0 mmol/l, range
2.2–8.9 mmol/l), and 2 (6%) patients had serum tri-
glyceride levels >5 mmol/l (median 1.5 mmol/l,
range 0.7–5.4 mmol/l), cut-off levels in the non-
fasting state indicating increased risk of future cardio-
vascular events.21 One patient had a prior diagnosis of
type II diabetes mellitus, controlled with metformin;
no patient had a non-fasting glucose of
>11.1 mmol/l, although serum insulin (median
77 pmol/l (11.1 mIU/l), range 10–1811 pmol/l
(1.4–260.8 mIU/l)) was ≥235 pmol/l (33.8 mIU/l)
in 8 (26%) of the 31 patients in whom it was
measured, a non-fasting level independently associ-
ated with an almost twofold increased relative risk
of future coronary heart disease events.22,23
Relationships between health-related quality of
life and cardiovascular and respiratory
parameters
There was a negative correlation between overall
health-related quality of life as measured by EORTC
QLQ-C30 and serum NT-pro-BNP level (P= 0.012,
r=−0.4). The dyspnoea score of EORTC QLQ-C30
varied widely between individuals (median 33, range
0–100) and correlated with BMI (P= 0.001, r= 0.6).
Discussion
Modern management strategies have progressively
improved the prognosis of myeloma to the extent
that it may be regarded as a ‘chronic cancer’ in
many patients. However, even when disease activity
is controlled, and active treatment discontinued,
Samuelson et al. Cardiorespiratory abnormalities in advanced myeloma
Hematology 2016 VOL. 21 NO. 5 275
patients may be significantly compromised by a cumu-
lative burden of problems related to myeloma, its treat-
ment, and advancing age.
We have analysed a cohort of patients, which argu-
ably represent a typical cross-section of advanced but
stable myeloma patients in a tertiary referral HSCT
centre. We selected patients with advanced and
heavily pre-treated myeloma, and all patients had
been exposed to at least one HSCT treatment and
one further line of therapy for progressive disease.
The majority of patients have had one or two
autologous HSCT procedures, and a minority have
had an allogeneic HSCT, although all patients have
had at least one further treatment for relapsed
disease. Importantly, in order to exclude the con-
founding effects of active myeloma and the acute tox-
icity of treatment, all patients had controlled disease
and were in stable plateau phase and off active
treatment.
Although cardiovascular and respiratory late effects
are recognized following curative treatments for
cancer, including HSCT,9,24 this study is the first
time that these cardiorespiratory aspects have been
examined specifically in long-term survivors of
myeloma following several lines of intensive treatment.
The major findings were a high prevalence of sub-
clinical cardiovascular and respiratory abnormalities,
which would be otherwise undetected by clinical
examination. The impact of such unrecognized cardi-
ovascular and respiratory abnormalities on aspects of
quality of life, including dyspnoea and its effect on
physical activity, may be significant, and warrants
further investigation. Simple lifestyle modifications
may also be important. For example, the majority of
our cohort was overweight or obese, which signifi-
cantly correlated with dyspnoea.
Cardiac abnormalities and cardiovascular risk
factors
Despite normal or near normal cardiovascular history
and physical examination, we found a high prevalence
of sub-clinical cardiac abnormalities on specialized
testing, with over 60% having an abnormality of
ECG or echocardiogram. In addition, serum NT-
pro-BNP level, a marker of cardio-renal strain and
potential ventricular dysfunction, was raised
(>15 pmol/l (125 pg/ml)) in 50% of patients and to
>47 pmol/l (400 pg/ml), the threshold for the investi-
gation of frank heart failure, in 22%.25 The association
between raised BNP and the future development of
symptomatic heart failure in patients undergoing
intensive chemotherapy treatment and stem cell trans-
plantation has been demonstrated in a previous obser-
vational study, and confirms the increased risk of overt
ventricular failure in those of our cohort with signifi-
cantly raised levels.26
The majority of the ECG and echocardiographic
findings appear to relate to markers of left atrial dila-
tation and LVH, suggesting a pattern of cardiac injury
from myeloma treatments that causes a rise in left ven-
tricular compliance. Myocardial fibrosis or changes of
the intercellular matrix may play a role here. It seems
likely that the elevated serum NT-pro-BNP levels
found in half of our cohort are also due to this effect
as there was little evidence of left ventricular systolic
dysfunction or major heart valve disease whilst renal
dysfunction affected a small proportion of our
cohort only. In the long term, raised left ventricular
compliance may predispose to the development of
atrial fibrillation (as was found in one subject at
screening), and in turn to cardio-embolic stroke, as
well as a poorer exertional capacity and frank heart
failure. It is noteworthy that the NT-pro-BNP level
correlated significantly with poorer quality of life
scores and a reduced exertional capacity due to early
heart failure could be the mechanism of that
correlation.
We have found frequent ECG and echocardiogram
abnormalities and a high prevalence of elevation of
natriuretic peptide levels in a cohort of stable but
intensively treated myeloma patients. Historical epide-
miological studies shed light on the potential signifi-
cance of these findings. In a cohort of 831 men aged
55–59 years selected from general US populations,
abnormalities on a baseline ECG were found in
17.8% and the presence of such abnormalities pre-
dicted a doubling of death rates and coronary events
during 11 years of follow-up compared to those with
a normal ECG.27 In comparison, 40% of our subjects
had such prognostically significant ECG changes
according to the criteria of this study (ECG P wave
enlargement was not included). The rate of echocar-
diographic abnormalities in the general population
was studied in 3272 people of similar age and gender
distribution to our cohort in Norway.28
Echocardiogram abnormalities were found in 9% of
the general population, a much lower incidence than
the 50% rate of echocardiogram abnormalities in our
study. Fifteen subjects in our cohort (47%) had ECG
or echocardiogram evidence of left atrial hypertrophy,
an abnormality that has been clearly linked to a sub-
stantially increased risk of stroke and death in the
general population.29 Thus it seems likely that the fre-
quent sub-clinical ECG and echocardiogram abnorm-
alities found in our stable and intensively treated
myeloma patients will translate into elevated cardio-
vascular morbidity and mortality with increasing dur-
ation of survival.
The most significant finding in our study is the fre-
quency and magnitude of activation of the natriuretic
peptide system. Fifty percent had values above the
normal value defined by Hildebrandt et al.12 and,
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more strikingly, 41% of our cohort exceeded the age-
and sex-stratified upper 97.5th percentile value for
NT pro-BNP as defined by Galasko et al.30 in
healthy subjects. Only 4 of the 32 (13%) myeloma
patients had a NT pro-BNP level below the median
values defined in their study. Elevated natriuretic
peptide levels, particularly NT-pro-BNP, have been
shown to predict mortality outcomes in chronic heart
failure, hypertension, acute coronary syndromes,
those at elevated cardiac risk, and normal popu-
lations.31 In two community cohorts minimally elev-
ated levels of NT pro-BNP predicted all cause and
cardiovascular mortality among apparently healthy
subjects32,33 and this power persists after adjustment
for clinical and echocardiographic factors.34 It is now
believed that natriuretic peptide system activation
may be secondary to inflammation, fibrosis, and
hypertrophy at vascular level as well as clinically
overt myocardial stretch and ventricular hypertro-
phy.31 Thus, NT pro-BNP is an important marker
for preclinical cardiovascular disease. The question
of whether NT pro-BNP levels can identify patients
who may benefit from early intervention remains
under investigation; reduced rates of progression to
heart failure were found in one trial of NT pro-BNP-
guided cardiovascular intervention in middle-aged
subjects at elevated cardiovascular risk,35 a cohort
somewhat analogous to the myeloma patients studied
here.
The causes for the cardiovascular abnormalities in
our study are likely to be multiple and too complex
to explain by a study of this size. Specifically it is not
possible to identify a responsible therapeutic agent.
The cumulative anthracycline dose was relatively low
(at <360 mg/m2) and dose did not correlate with the
observed cardiac anomalies. However, both cardio-
toxic chemotherapy and the late effects of other poten-
tially cardiotoxic agents, such as multiple doses of
‘palliative’ thoracic radiotherapy, warrant consider-
ation, both on a routine clinical basis, and in further
clinical studies. The correlation between serum NT-
pro-BNP and serum ferritin levels supports a link
between transfusional iron loading and early cardiac
dysfunction and raises the question of whether more
accurate measurement of cardiac iron levels by
cardiac magnetic resonance imaging, and intervention
by venesection and/or iron chelation, should be con-
sidered in this patient group.
The limited prognosis of myeloma and the long-
term horizon for coronary risk factors have meant
that cardiovascular lifestyle modification and the
treatment of dyslipidaemia, diabetes, and hypertension
were previously challenging to justify. However,
increased prevalence of cardiovascular risk factors
such as hypertension and dyslipidaemia in the post-
transplant setting has been recently recognized in
both autologous and allogeneic HSCT recipients.36
While pre-existing risk factors of diabetes, smoking,
and alcohol excess do not appear to be especially
raised in our sample compared with the adult UK
population as a whole, a significant proportion have
evidence of raised cholesterol, triglycerides, and/or
insulin, all of which may predict increased risk of
future cardiovascular morbidity.37,38 In addition, a
proportion of our cohort had potentially undiagnosed
but treatable hypertension and most were overweight
or obese.
The detection of cardiovascular abnormalities in
over half of the patients in our cohort raises the ques-
tion of whether systematic screening may be justified.
For example, early detection of cardiovascular
abnormalities and risk factors may result in more
effective intervention in this expanding group of
patients. Given the high proportion of patients with
raised serum NT-pro-BNP levels, its measurement
for the detection of cardiac dysfunction in intensively
treated myeloma patients could be considered as a
screening tool for cardiac damage. Patients with
early cardiac dysfunction may be treated with angio-
tensin-converting enzyme inhibitors and other anti-
heart failure medication.4,9,39 Systematic screening
and appropriate medical treatment of risk factors
such as dyslipidaemia, hypertension, abdominal
obesity, diabetes, and iron overload should also be
considered. The use of prognosticators, such as the
10-year CVD risk calculator from the National
Heart, Lung and Blood Institute (www.nhlbi.nih
.gov), could now be used in long-term myeloma
survivors.
Respiratory abnormalities
Few patients in our cohort had abnormal standardized
respiratory clinical examinations, but almost half had
spirometry results indicating airway pathology. The
majority had restrictive or mixed pictures rather than
obstructive. In addition, 43% of patients had reduced
maximum inspiratory and/or expiratory pressures,
causes of which have been shown to include neuromus-
cular weakness, malnutrition, cachexia, and/or pain.40
Whilst spirometry results would be expected to
deteriorate with age, it should be noted that expected
values are age-corrected and the results from many
of our myeloma patients are therefore inferior to
those of the general population of a similar age. The
cause of the sub-clinical respiratory dysfunction is
likely to be multi-factorial, with a combination of
disease and treatment factors, including chemother-
apy, HSCT, thoracic radiotherapy, and recurrent res-
piratory infections. Steroid myopathy, a cause of
respiratory muscle weakness among cancer patients,
may have been a factor as cumulative steroid dosage
was high.41 Evidence for cachexia was rare in the
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group, although high starting BMI may have masked
weight loss, and a paper recently published by our
group has shown that a significant number of these
patients have abnormal body composition – specifi-
cally ‘sarcopenia’.6 Smoking at time of assessment
was rare, but the impact of previous smoking may
have contributed.
These respiratory data are in agreement with pub-
lished findings in patients with other heavily treated
malignancies, but are previously unreported in
myeloma.7,42 Limitation in respiratory reserve may
have a significant impact on both quality of life and
survival in myeloma, where infection remains the
leading single cause of death.43 Further investigation
is warranted to differentiate the contributions of mus-
cular weakness, pain, fatigue, dyspnoea, high BMI,
and genuine airway pathology in this picture as well
as any modifiable predisposing or iatrogenic factors.
In the meantime, simple measures such as weight/
BMI reduction and smoking cessation may improve
respiratory function.
Conclusions
Long-term survivors of myeloma are now a distinct
and increasing population who accumulate the ‘late
effects’ not only of HSCT, but also several other
lines of treatment. Our study demonstrates a high
prevalence of sub-clinical cardiovascular and respirat-
ory compromise, above that expected in an age-
matched non-myeloma population and unlikely to be
detected by routine monitoring in the myeloma clinic
unless specific screening such as echocardiography or
measurement of serum NT pro-BNP levels is under-
taken. The impact of such sub-clinical cardiovascular
and respiratory abnormalities on aspects of quality
of life, including dyspnoea and its effect on physical
activity, and on survival may be significant and war-
rants further investigation. The data in this study
provide a starting point for the development of specific
cardiovascular and respiratory screening guidance
within the long-term comprehensive supportive care
of myeloma patients, as well as a basis for future
research, including interventional studies.2
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